Sanofi: first results from study on dupilumab.
(CercleFinance.com) - Sanofi and Regeneron have announced that LIBERTY ASTHMA QUEST the pivotal phase 3 study which is dedicated to dupilumab and which is being conducted with a large population of patients with persistent uncontrolled asthma, has reached both its primary endpoints.
Dupilumab, in addition to standard treatments, has helped to reduce the number of severe asthma crises and improve breathing. After 52 weeks with a dose of 300 mg, it reduced the number of crises by 46% in the general population covered by the study.
After 12 weeks, in the group treated with a dose of 300 mg of dupilumab, compared to the group receiving placebo, the maximum expiratory volume per second amounted to 130 ml (9%) in the study's general population.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Dupilumab, in addition to standard treatments, has helped to reduce the number of severe asthma crises and improve breathing. After 52 weeks with a dose of 300 mg, it reduced the number of crises by 46% in the general population covered by the study.
After 12 weeks, in the group treated with a dose of 300 mg of dupilumab, compared to the group receiving placebo, the maximum expiratory volume per second amounted to 130 ml (9%) in the study's general population.
Copyright (c) 2017 CercleFinance.com. All rights reserved.